Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial

Background: Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure. There are in vitro, animal studies and pre-clinical data suggesting that statins may be beneficial in ALI. The Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter, prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI.

Methods/Design: Patients fulfilling the American-European Consensus Conference Definition of ALI will be randomized in a 1: 1 ratio to receive enteral simvastatin 80 mg or placebo once daily for a maximum of 28 days. Allocation to randomized groups will be stratified with respect to hospital of recruitment and vasopressor requirement. Data will be recorded by participating ICUs until hospital discharge, and surviving patients will be followed up by post at 3, 6 and 12 months post randomization. The primary outcome is number of ventilator-free days to day 28. Secondary outcomes are: change in oxygenation index and sequential organ failure assessment score up to day 28, number of non pulmonary organ failure free days to day 28, critical care unit mortality; hospital mortality; 28 day post randomization mortality and 12 month post randomization mortality; health related quality of life at discharge, 3, 6 and 12 months post randomization; length of critical care unit and hospital stay; health service use up to 12 months post-randomization; and safety. A total of 540 patients will be recruited from approximately 35 ICUs in the UK and Ireland. An economic evaluation will be conducted alongside the trial. Plasma and urine samples will be taken up to day 28 to investigate potential mechanisms by which simvastatin might act to improve clinical outcomes.

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

OBJECTIVE: To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," published in 2004. DESIGN: Modified Delphi method with a consensus conference of 55 international experts, several subsequent meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. This process was conducted independently of any industry funding. METHODS: We used the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system to guide assessment of quality of evidence from high (A) to very low (D) and to determine the strength of recommendations. A strong recommendation (1) indicates that an intervention's desirable effects clearly outweigh its undesirable effects (risk, burden, cost) or clearly do not. Weak recommendations (2) indicate that the tradeoff between desirable and undesirable effects is less clear. The grade of strong or weak is considered of greater clinical importance than a difference in letter level of quality of evidence. In areas without complete agreement, a formal process of resolution was developed and applied. Recommendations are grouped into those directly targeting severe sepsis, recommendations targeting general care of the critically ill patient that are considered high priority in severe sepsis, and pediatric considerations. RESULTS: Key recommendations, listed by category, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures before antibiotic therapy (1C); imaging studies performed promptly to confirm potential source of infection (1C); administration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D); reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7-10 days of antibiotic therapy guided by clinical response (1D); source control with attention to the balance of risks and benefits of the chosen method (1C); administration of either crystalloid or colloid fluid resuscitation (1B); fluid challenge to restore mean circulating filling pressure (1C); reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); vasopressor preference for norepinephrine or dopamine to maintain an initial target of mean arterial pressure > or = 65 mm Hg (1C); dobutamine inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated protein C in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for postoperative patients). In the absence of tissue hypoperfusion, coronary artery disease, or acute hemorrhage, target a hemoglobin of 7-9 g/dL (1B); a low tidal volume (1B) and limitation of inspiratory plateau pressure strategy (1C) for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS); application of at least a minimal amount of positive end-expiratory pressure in acute lung injury (1C); head of bed elevation in mechanically ventilated patients unless contraindicated (1B); avoiding routine use of pulmonary artery catheters in ALI/ARDS (1A); to decrease days of mechanical ventilation and ICU length of stay, a conservative fluid strategy for patients with established ALI/ARDS who are not in shock (1C); protocols for weaning and sedation/analgesia (1B); using either intermittent bolus sedation or continuous infusion sedation with daily interruptions or lightening (1B); avoidance of neuromuscular blockers, if at all possible (1B); institution of glycemic control (1B), targeting a blood glucose < 150 mg/dL after initial stabilization (2C); equivalency of continuous veno-veno hemofiltration or intermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1A); use of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limitation of support where appropriate (1D). Recommendations specific to pediatric severe sepsis include greater use of physical examination therapeutic end points (2C); dopamine as the first drug of choice for hypotension (2C); steroids only in children with suspected or proven adrenal insufficiency (2C); and a recommendation against the use of recombinant activated protein C in children (1B). CONCLUSIONS: There was strong agreement among a large cohort of international experts regarding many level 1 recommendations for the best current care of patients with severe sepsis. Evidenced-based recommendations regarding the acute management of sepsis and septic shock are the first step toward improved outcomes for this important group of critically ill patients.

Évaluation d’une expérience de conférence citoyenne : analyse éthique

Un intérêt grandissant pour le rôle du citoyen dans la prise de décision concernant la vie publique se développe depuis les dernières années. Le développement et la mise en oeuvre de divers mécanismes de participation citoyenne, comme les conférences citoyennes, témoignent de cet intérêt. Nombre de ces expériences ont fait l'objet d'une évaluation, mais essentiellement au niveau de l'efficacité ou du succès de l'exercice. Peut-on les évaluer sur le plan de l’éthique? Quels sont les défis éthiques posés par les mécanismes de participation citoyenne? Ce mémoire évalue une expérience de conférence citoyenne portant sur les avancées de la biologie humaine à l’ère de la génomique mise sur pied par le Groupe de recherche en bioéthique (GREB) de l’Université de Montréal en 2005. À l’aide du concept de l’éthique de la discussion, telle que proposée par quatre auteurs québécois, une analyse qualitative est effectuée sur six documents rédigés dans le cadre de la conférence. Deux catégories de résultats sont discutées. D’abord, les divers éléments relatifs à la conférence citoyenne qui ont soulevé notre attention. Ensuite, les préoccupations des participants en lien avec la science, la société et la participation. Une meilleure compréhension des aspects éthiques auxquels on devrait accorder une attention particulière contribuera à l’amélioration du mécanisme de conférence citoyenne et à son utilisation à long terme.

Diferencia venoarterial de PCO2 como predictor de disfunción miocárdica en pacientes pediátricos con sepsis severa y choque séptico

El objetivo de este estudio, es determinar la capacidad de la diferencia venoarterial de de pCO2, como predictor de disfunción miocárdica en pacientes pediátricos con sepsis severa y choque séptico en la Unidad de Cuidado Intensivo Pediátrico de la Fundación Cardio Infantil. El documento eviado corresponde a un informe parcial de un estudio en curso en la Fundación CardioInfantil.

Correlación SO2/FiO2 con PaO2/FiO2 en niños en ventilación mecánica a grandes alturas : estudio multicéntrico

Cambios en la PaO2 se correlacionan de manera positiva con cambios en la SO2 permitiendo determinar la severidad de la hipoxemia. La búsqueda de un predictor que de forma no invasiva detecte pacientes con mayor compromiso pulmonar ha ganando auge; estableciendo los grados de hipoxemia moderada o severa como criterios para LPA y SDRA, a partir de los valores de PaO2/FiO2 y su correlación con la SO2/FiO2. No se conocen los valores de SO2/FiO2 que a más de 2500msnm permitan identificar la severidad de la hipoxemia en pediatría. Metodología: estudio de correlación y predicción en pacientes de un mes a 18 años de edad admitidos a UCIP, con soporte ventilatorio mecánico y análisis de gases arteriales seriados en dos Hospitales de referencia. Análisis de relación lineal y determinación de la correlación SOFiO2 y PaFiO2 a partir de 430 mediciones. Resultados: el estudio mostro una media para PaO2/FiO2 de 192,12 (DS+75,62) y para SO2/FiO2 de 208,61 (DS+62,79). La correlación SO2/FiO2 y Pa/FiO2 fue positiva y moderada-alta (r= 0,702;p<0.01). A partir de la regresión lineal entre las variables se obtuvo la ecuación de determinación PaO2/FiO2 = (0.92xSO2/FIO2) - 12, con sensibilidad y especificidad de 76% para detectar hipoxemia severa (SO2/FiO2<231), y sensibilidad de 74% y especificidad de 71% para hipoxemia moderada (SO2/FiO2<340). Discusión: los hallazgos obtenidos son muy útiles desde el punto de vista clínico para detectar rápidamente pacientes con hipoxemia moderada y severa, con riesgo potencial de deterioro, cuando no se dispone de línea arterial ó gases arteriales.